Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.

Nitin Jain Lisa J Croner John N Allan Tanya Siddiqi Alessandra Tedeschi Xavier C Badoux Karl Eckert Leo W K Cheung Anwesha Mukherjee James P Dean Edith Szafer-Glusman John Francis Seymour

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

First-line fixed-duration combination treatment with ibrutinib plus venetoclax may mitigate development of resistance mechanisms associated with continuous single-agent targeted therapies, allowing for effective retreatment.

Keyphrases

chronic lymphocytic leukemia
multiple sclerosis
tyrosine kinase
rheumatoid arthritis
disease activity